It has been reported that molecular diagnosis for guiding targeted therapies, such as KRAS and BRAF mutation test in colorectal cancer [38], HER-2 amplification test in breast cancer [39], and BRAF mutation test in melanoma [40], become more and more important in cancer management. This evidence concerns the gene KRAS and cancer.